

[Home \(/\) / Advocacy and Issues \(/Advocacy-and-Issues\) /](#)[Key Issues \(/Advocacy-and-Issues/Key-Issues\) /](#)[Opioids \(/Advocacy-and-Issues/Key-Issues/Opioids\) /](#)[Model State Law to Improve Access to Medications for Opioid Use Disorder from Pharmacists](#)

Add To Favorites

<https://www.addtoany.com/share?url=https%3A%2F%2Fwww.ashp.org%2FAdvocacy-and-Issues%2FKey-Issues%2FOpioids%2FModel-State-Law-to-Improve-Access-to-Medications-for-Opioid-Use-Disorder-from-Pharmacists>

Model State Law to Improve Access to Medications for Opioid Use Disorder from Pharmacists

Executive Summary

Congress recently eliminated the X-waiver, a federal barrier to pharmacists prescribing medications for opioid use disorder (MOUD). States can now use pharmacists to improve access to MOUD. This model legislation was developed to help states expand access to MOUDs and curb the opioid crisis in their communities.

Explanation of Key Elements:

1. Provide clear authority for pharmacists to initiate MOUD

The model legislation establishes clear authority for physicians and institutions to establish agreements with pharmacists to manage medication therapy to treat opioid use disorder. It should provide flexibility for these agreements to include a statewide protocol, collaborative practice agreement, or institutional protocol.

2. Establish a timeline for board of pharmacy action on buprenorphine

The elimination of the X-waiver was intended to expand access to buprenorphine. Legislation should direct the board of pharmacy to establish a model statewide protocol for pharmacist initiation and management of buprenorphine therapy for opioid use disorder. A model protocol is available here ([/Advocacy-and-Issues/Key-Issues/Opioids/model-MOUD-prescribing-protocol](#)).

3. Ensure pharmacists comply with federal registration and training requirements

Federal law requires that pharmacists register with the DEA and complete certain training requirements prior to prescribing controlled substances to treat opioid use disorder. State law should align with these federal prescribing requirements.

4. Remove any pre-existing state barriers to MOUD prescribing

Most MOUDs, including buprenorphine, are controlled substances. Some state Controlled Substances Acts or Pharmacy Practice Acts may legacy prohibitions against pharmacists prescribing controlled substances. These must be removed to allow prescribing of MOUD.

5. Create a mechanism for Medicaid to pay for these pharmacist services

If the state does not have an existing Medicaid payment mechanism for clinical services provided by pharmacists, add this authority to the Medicaid statute to allow reimbursement of pharmacist services related to MOUD management.

6. Create a mechanism for commercial insurance to pay for these pharmacist services

If the state does not have an existing commercial insurance payment mechanism for clinical services provided by pharmacists, add this authority to the insurance statute, to allow reimbursement of pharmacist services related to MOUD management. Some states may have separate statutes governing group health plans, HMOs, or other plan types. Replicate this language in those statutes.

Model legislative text:

Pharmacist-Supported Access to Medications for Opioid Use Disorder

(a) A pharmacist may initiate, modify, discontinue, or administer medications for the treatment of opioid use disorder, opioid withdrawal symptoms, overdose prevention, and opioid side effects, and taper or discontinue opioids, pursuant to a protocol, collaborative practice agreement, or institutional privileging agreement, to the extent authorized by federal law.

(b) The Board of Pharmacy shall establish a statewide protocol for pharmacist treatment of opioid use disorder, including but not limited to initiation of buprenorphine-containing treatments, not later than 180 days after the date of enactment of this provision.

(c) A pharmacist authorized to issue an order to initiate or adjust a medication assisted treatment that is a controlled substance shall register with the federal Drug Enforcement Administration and complete the training required by Section 303 of the Controlled Substances Act (21 U.S.C. 823).

(d) [If applicable] Delete any language in the State Pharmacy Practice Act and State Controlled Substances Act prohibiting pharmacists from ordering controlled substances and clarify that the state shall permit a pharmacist to register with the federal Drug Enforcement Administration to provide services outlined in the Controlled Substances Act.

(e) Medicaid [and its Medicaid managed care issuers] shall provide direct payment to a pharmacist providing covered health care services authorized in this legislation to a Medicaid beneficiary at a rate no less than that of other health care providers for providing the same service.

(f) For health plans, policies, contracts, or agreements issued, amended, adjusted, or renewed on or after [insert date of next plan year]:

(1) Benefits may not be denied for any health care service performed by a licensed pharmacist if:

(A) The service performed was within the lawful scope of the pharmacist's license;

(B) The plan would have provided benefits if the service had been performed by another

health care provider; and

(2) Health benefit plans or issuers, policies, contracts, or agreements that delegate credentialing to contracted health care facilities shall accept credentialing for pharmacists employed or contracted by those facilities. Health plans or issuers shall reimburse facilities for covered services provided by network pharmacists within the pharmacists' scope of practice per negotiations with the facility.



(1)

RELATED ASHP SITES

- AJHP Journal (<http://www.ajhp.org>)
- AHFS Drug Information (<http://www.ahfsdruginformation.com>)
- ASHP Connect (<http://connect.ashp.org>)
- ASHP Foundation (<http://www.ashpfoundation.org>)
- ASHP Global (<https://www.ashp.org/global>)
- ASHP eBooks (<http://digital.ashp.org>)
- ASHP Learning Center (<http://elearning.ashp.org/>)
- ASHP Well-being & You (<https://wellbeing.ashp.org/>)
- Pharmacy Technician Society (<https://www.pharmtechsociety.org/>)
- SafeMedication.com (<http://www.safemedication.com>)

PARTNER WITH ASHP

- Corporate Support Policy (</About-ASHP/Corporate-Support-and-Advertising/Corporate-Support>)
- Business Opportunities (</About-ASHP/Corporate-Support-and-Advertising/Business-Opportunities>)
- Drug Database Licensing (</Products-and-Services/Database-Licensing-and-Integration>)
- Advertising (<https://www.ashp.org/About-ASHP/Corporate-Support-and-Advertising/Advertising>)

NEWS AND MEDIA ([HTTPS://WWW.ASHP.ORG/NEWS-AND-MEDIA](https://www.ashp.org/news-and-media))

ASHP CAREERS ([/ABOUT-ASHP/ASHP-CAREERS](/About-ASHP/ASHP-Careers))

CONTACT US ([/CONTACT-US](/Contact-US))



[HTTP://WWW.ASHP.ORG](http://www.ashp.org)

[HTTPS://WWW.ASHP.ORG/NEWS-AND-MEDIA](https://www.ashp.org/news-and-media)

[HTTPS://WWW.ASHP.ORG/ABOUT-ASHP/CORPORATE-SUPPORT-AND-ADVERTISING/ADVERTISING](https://www.ashp.org/about-ashp/corporate-support-and-advertising/advertising)

[HTTPS://WWW.ASHP.ORG/ABOUT-ASHP/CAREERS](https://www.ashp.org/about-ashp/careers)

[HTTPS://WWW.ASHP.ORG/CONTACT-US](https://www.ashp.org/contact-us)

[HTTPS://WWW.ASHP.ORG/OFFICIAL](https://www.ashp.org/official)

© Copyright 2024 American Society of Health-System Pharmacists. All Rights Reserved.